NEW YORK, NY — November 27, 2025: Protagenic Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced receipt of a Nasdaq non-compliance notice citing deficiencies under Listing Rules 5550(b)(1) for minimum stockholders’ equity and 5250(c)(1) for timely filing of required financial reports. The notification follows the Company’s recently filed Transition Report on Form 10-QT and the delayed submission of its Form 10-Q for the quarter ended September 30, 2025. Because Protagenic had only recently regained compliance and remains under a mandatory monitoring period, the Nasdaq Listing Qualifications Staff has issued a preliminary determination to delist the Company’s securities, triggering a critical juncture for the biotech firm as it prepares to request a hearing before a Nasdaq Hearings Panel.
Science Significance
While the non-compliance notice does not directly relate to the Company’s scientific programs, the announcement subtly underscores how financial sustainability and regulatory adherence play a foundational role in supporting long-term biopharmaceutical R&D. Protagenic is developing therapeutics for neurological and neuropsychiatric disorders, areas already marked by high translational complexity and extended development timelines. Without adequate market stability, companies pursuing CNS-focused innovation may face delays in advancing preclinical assets, generating clinical data, and sustaining the quality systems needed to support cGCP-aligned trials. The continued listing of its securities during the stay period provides a temporary safeguard against disruptions to ongoing research activities, but the scientific trajectory ultimately depends on restoring regulatory and financial compliance.
Regulatory Significance
The situation highlights the intersection between corporate compliance and broader regulatory expectations within the life-sciences sector. Nasdaq Listing Rules 5550(b)(1) and 5250(c)(1) serve as accountability mechanisms that ensure public companies maintain transparent reporting, timely disclosures, and adequate shareholder equity—all essential components of governance integrity. For organizations operating in drug development, these layers of oversight complement formal scientific and quality-system regulatory frameworks such as cGMP, cGLP, and cGCP, reinforcing the expectation that biopharma companies uphold consistent standards across both operational and financial domains. Protagenic’s imminent filing of its delayed Form 10-Q will play a pivotal role in its appeal before the Panel, as the Company prepares to show a credible remediation strategy.
Business Significance
Advertisement
From a business perspective, the dual deficiencies present serious implications for investor confidence, liquidity, and long-term corporate viability. Nasdaq delisting can reduce access to capital markets, constrain strategic partnerships, and complicate future financing efforts—particularly critical for a clinical-stage company reliant on sustained funding to progress therapeutic candidates. Protagenic’s stock will continue trading on The Nasdaq Capital Market during the automatic stay and, if granted, the extended stay, but the Company acknowledges there is no assurance that additional time will be provided or that compliance will be regained. The hearing process will determine whether Protagenic can implement corrective actions to restore shareholder equity, resolve reporting gaps, and re-establish alignment with listing standards.
Patients’ Significance
For patients awaiting new therapeutic options for neurological and neuropsychiatric conditions, financial and listing instability introduces potential uncertainty. The development of innovative CNS-targeted drugs requires uninterrupted clinical activity, reliable funding, and rigorous adherence to regulatory quality frameworks. Although the notice does not indicate immediate impact on clinical progress, disruptions in corporate stability can indirectly influence timelines, resource allocation, and trial continuity, all of which shape how quickly patients may gain access to novel treatments. Protagenic’s appeal and its efforts to re-establish compliance will be closely watched by stakeholders invested in advancing mental-health-focused therapeutics.
Policy Significance
The announcement also reinforces the role of market oversight policies that ensure transparency and protect public investors. Nasdaq’s monitoring periods and mandatory corrective procedures help ensure that companies maintain consistent operational discipline, particularly after recent compliance lapses. These structures align with broader national expectations for corporate accountability, especially in sectors whose financial health directly influences public-facing scientific and clinical progress. Protagenic’s case may serve as a reminder of the need for robust reporting infrastructures and proactive compliance monitoring within small-cap biotech firms navigating volatile capital environments.
As Protagenic Therapeutics prepares its appeal to the Nasdaq Hearings Panel, the Company faces a critical window to restore compliance, stabilize its market position, and maintain continuity in its scientific mission. The outcome will determine whether the Company can sustain the financial and regulatory footing required to advance its therapeutic pipeline while preserving investor confidence and safeguarding long-term development plans.
Source: Protagenic Therapeutics, Inc. press release
